Prevention and monitoring of anthracycline-induced cardiotoxicity in breast cancer patients

Authors

DOI:

https://doi.org/10.5281/zenodo.7308173

Keywords:

antraciclinas, câncer de mama, cardiotoxicidade, prevenção

Abstract

Introduction: Anthracyclines are the most effective chemotherapy drugs for the treatment of breast cancer, but they have cardiotoxic effects. Objective: To investigate methods used to monitor and prevent cardiotoxicity caused by anthracyclines in breast cancer patients. Methods: Integrative literature review carried out through searches in the Biblioteca Virtual de Saúde (BVS). Results: It is recommended to check left ventricular ejection fraction every three months and arterial stiffness until the end of treatment. Ramipril obtained cardioprotective effects during the use of anthracyclines. Lisinopril associated with bisoprolol had good cardioprotective results. The use of statins during treatment reduced hospitalization rates for heart failure. Platycondon grandiplorum prevented cardiotoxicity. As an alternative for replacing common anthracyclines, liposomal anthracyclines are used. Conclusion: There is a need to increase the production of studies on the drugs and monitoring methods that were analyzed.

Downloads

Download data is not yet available.

Author Biographies

Paloma Bianca Veras Bastos, Escola Superior de Ciências da Saúde, DF, Brasil

[1] Graduada em Enfermagem pelo Centro Universitário do Distrito Federal (2020). Pós-graduanda em Oncologia em módulo Residência Multiprofissional pela Secretaria do Estado de Saúde do Distrito Federal (SES/DF). Integrante da Liga de Oncologia (2020/2021). Monitora em Saúde da Mulher (2020). Discente participante da iniciação científica com trabalhos relacionados a saúde mental (2019/2020). Atividades de pesquisa científica relacionadas a: saúde mental; oncologia; saúde do adulto; saúde da mulher

Renata Costa Fortes, Escola Superior de Ciências da Saúde, DF, Brasil

[2] Pós-Doutora em Psicologia com Metodologia de Revisão Sistemática pela Universidad de Flores, Buenos Aires. Doutora e Mestra em Nutrição Humana pelo Curso de Pós-Graduação em Nutrição Humana da Faculdade de Ciências da Saúde da Universidade de Brasília (UnB/DF). Especialista em Nutrição Aplicada à Terceira Idade pelo Centro Universitário Estácio, Especialista em Abordagem Multidisciplinar em Oncologia pela Faculdade Única (Grupo Prominas), Especialista em Manuseio Nutricional na Cirurgia Bariátrica pela Faculdade Unylea, Especialista em Nutrição Clínica pela Secretaria de Estado de Saúde do Distrito Federal (SES/DF), Especialista em Clínica e Terapêutica Nutricional pelo Instituto de Pesquisa Capacitação e Especialização (IPCE), Especialista em Nutrição Clínica, Enteral e Parenteral pelo GANEP, Especialista em Nutrição Clínica pela ASBRAN, Especialista em Gestão de Redes de Atenção à Saúde e possui Aperfeiçoamento em Atenção Domiciliar pela Fiocruz. Graduada em Nutrição pela Universidade Federal de Ouro Preto - Minas Gerais (UFOP/MG)

Elciane Falcão de Mesquita, Escola Superior de Ciências da Saúde, DF, Brasil

[3] Possui graduação em Bacaharelado em enfermagem pela Universidade Federal da Paraíba (2001). Atualmente é enfermeira do Hospital regional de samambaia e do Hospital das Forças Armadas

References

Sandamali, J. A. N., Hewawasam, R. P., Fernando, M. A. C. S. S., Jayatilaka, K. A. P. W., Madurawe, R. D., Sathananthan, P. P., Ekanayake, U., & Horadugoda, J. (2020). Anthracycline-induced cardiotoxicity in breast cancer patients from southern sri lanka: An echocardiographic analysis. BioMed Research International, 2020, e1847159. https://doi.org/10.1155/2020/1847159

Varghese, S. S., Eekhoudt, C. R., & Jassal, D. S. (2021). Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer. Molecular and Cellular Biochemistry, 476(8), 3099–3109. https://doi.org/10.1007/s11010-021-04152-y

CloseDeleteEdit

Bozza, W. P., Takeda, K., Alterovitz, W.-L., Chou, C.-K., Shen, R.-F., & Zhang, B. (2021). Anthracycline-induced cardiotoxicity: Molecular insights obtained from human-induced pluripotent stem cell-derived cardiomyocytes (Hipsc-cms). The AAPS Journal, 23(2), 44. https://doi.org/10.1208/s12248-021-00576-y

Semeraro, G. C., Lamantia, G., Cipolla, C. M., & Cardinale, D. (2021). How to identify anthracycline-induced cardiotoxicity early and reduce its clinical impact in everyday practice. Kardiologia Polska (Polish Heart Journal), 79(2), 114–122. https://doi.org/10.33963/KP.15782

Araújo, W. C. O. (2020). Recuperação da informação em saúde: Construção, modelos e estratégias. http://www.repositorio.ufc.br/handle/riufc/52993

Słowik, A., Jagielski, P., Potocki, P., Streb, J., Ochenduszko, S., Wysocki, P., Gajos, G., & Konduracka, E. (2020). Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: Results of a prospective randomized study. Kardiologia Polska, 78(2), 131–137. https://doi.org/10.33963/KP.15163

Saleh, Y., Abdelkarim, O., Herzallah, K., & Abela, G. S. (2021). Anthracycline-induced cardiotoxicity: Mechanisms of action, incidence, risk factors, prevention, and treatment. Heart Failure Reviews, 26(5), 1159–1173. https://doi.org/10.1007/s10741-020-09968-2

Bojan, A., Torok-Vistai, T., & Parvu, A. (2021). Assessment and management of cardiotoxicity in hematologic malignancies. Disease Markers, 2021, 6616265. https://doi.org/10.1155/2021/6616265

Lazăr, D. R., Farcaş, A. D., Blag, C., Neaga, A., Zdrenghea, M. T., Căinap, C., Lazăr, F. L., Stef, A., & Căinap, S. S. (2021). Cardiotoxicity: A major setback in childhood leukemia treatment. Disease Markers, 2021, 8828410. https://doi.org/10.1155/2021/8828410

Gavila, J., Seguí, M. Á., Calvo, L., López, T., Alonso, J. J., Farto, M., & Sánchez-de la Rosa, R. (2017). Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: A Delphi study. Clinical and Translational Oncology, 19(1), 91–104. https://doi.org/10.1007/s12094-016-1508-y

Souza, C. A. de, Simões, R., Borges, K. B. G., Oliveira, A. N. de, Zogeib, J. B., Alves, B., Malachias, M. V. B., Drummond-Lage, A. P., & Rezende, B. A. (2018). Arterial stiffness use for early monitoring of cardiovascular adverse events due to anthracycline chemotherapy in breast cancer patients. A pilot study. Arquivos Brasileiros de Cardiologia, 111, 721–728. https://doi.org/10.5935/abc.20180168

Wihandono, A., Azhar, Y., Abdurahman, M., & Hidayat, S. (2021). The role of lisinopril and bisoprolol to prevent anthracycline induced cardiotoxicity in locally advanced breast cancer patients. Asian Pacific Journal of Cancer Prevention: APJCP, 22(9), 2847–2853. https://doi.org/10.31557/APJCP.2021.22.9.2847

Abdel-Qadir, H., Bobrowski, D., Zhou, L., Austin, P. C., Calvillo-Argüelles, O., Amir, E., Lee, D. S., & Thavendiranathan, P. (2021). Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: A propensity score‒matched cohort study. Journal of the American Heart Association, 10(2), e018393. https://doi.org/10.1161/JAHA.119.018393

Hao, W., Shi, Y., Qin, Y., Sun, C., Chen, L., Wu, C., Bao, Y., & Liu, S. (2020). Platycodon grandiflorum protects against anthracycline-induced cardiotoxicity in early breast cancer patients. Integrative Cancer Therapies, 19, 1534735420945017. https://doi.org/10.1177/1534735420945017

Downloads

Published

2022-11-09

How to Cite

BASTOS, P. B. V.; FORTES, R. C.; MESQUITA, E. F. de. Prevention and monitoring of anthracycline-induced cardiotoxicity in breast cancer patients. JRG Journal of Academic Studies, Brasil, São Paulo, v. 5, n. 11, p. 240–250, 2022. DOI: 10.5281/zenodo.7308173. Disponível em: http://www.revistajrg.com/index.php/jrg/article/view/399. Acesso em: 12 may. 2024.

Issue

Vol. 5 No. 11 (2022): Revista JRG de Estudos Acadêmicos

Section

Artigos

ARK

https://n2t.net/ark:/57118/JRG.v5i11.399

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.